rosiglitazone has been researched along with Pheochromocytoma in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aguilera, MC; Bronfman, FC; Bronfman, M; Contador, D; Fuenzalida, KM; Piderit, DG; QuiƱones, V; Ramos, PC; Rigotti, A | 1 |
Chang, MS; Choi, OK; Kim, SW; Kim, SY; Park, KS; Shin, CS | 1 |
2 other study(ies) available for rosiglitazone and Pheochromocytoma
Article | Year |
---|---|
Peroxisome proliferator-activated receptor gamma is a novel target of the nerve growth factor signaling pathway in PC12 cells.
Topics: Animals; Cell Survival; Gene Deletion; Nerve Growth Factors; PC12 Cells; Pheochromocytoma; PPAR gamma; Rats; Receptor, trkA; Receptors, Nerve Growth Factor; Recombinant Proteins; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription, Genetic; Transfection | 2005 |
Thiazolidinediones inhibit the growth of PC12 cells both in vitro and in vivo.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Caspase 3; Cell Proliferation; Cyclin E; Cyclin-Dependent Kinase 2; Humans; Ki-67 Antigen; Mice; Nerve Growth Factor; Neurons; PC12 Cells; Pheochromocytoma; Pioglitazone; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones | 2008 |